Mechlorethamine-based drug structures for intervention of central nervous system tumors

Ronald Bartzatt1

  • 1University of Nebraska, College of Arts & Sciences, Durham Science Center, 6001 Dodge Street, Omaha, Nebraska 68182 USA. rbartzatt@unomaha.edu.

Insights

This study analyzes thirteen drugs similar to mechlorethamine for treating central nervous system tumors. Agents 7 and 12 show the most promise due to favorable bioavailability and high brain penetration potential.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuro-oncology

Background:

  • Central nervous system (CNS) tumors are a significant cause of childhood cancer.
  • Pediatric brain tumor treatment requires specialized approaches distinct from adult care.
  • Mechlorethamine is a relevant alkylating agent, but related compounds may offer improved therapeutic profiles.

Purpose of the Study:

  • To identify and analyze drugs structurally similar to mechlorethamine for potential CNS tumor treatment.
  • To evaluate the physicochemical properties of these drugs concerning bioavailability and CNS penetration.
  • To develop a predictive model for designing novel alkylating agents targeting CNS tumors.

Main Methods:

  • Analysis of thirteen mechlorethamine-analogous drugs.
  • Assessment of molecular properties including Log P, formula weight, and polar surface area.
  • Application of hierarchical cluster analysis, principal component analysis, and multiple regression analysis.

Main Results:

  • All thirteen drugs adhered to the Rule of 5, indicating good oral bioavailability.
  • Agents 7 and 12 were identified as most similar to mechlorethamine via cluster and principal component analyses.
  • A predictive model was generated for designing similar alkylating agents with high CNS penetration (Log (Cbrain/Cblood) values).

Conclusions:

  • Drugs 7 and 12 possess favorable physicochemical properties for CNS tumor therapy.
  • The developed model can guide the design of new alkylating agents for pediatric brain cancers.
  • These findings support the development of novel therapeutic strategies for CNS malignancies.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...